Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taho PharmaceuticalsROCO:6467 -4.22%35 Quick Ratio is 15.11 as of Dec. 2025, which is 0% above its 10-year median of 15.09. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 998 Drug Manufacturers companies, Taho Pharmaceuticals ranks better than 96.99% on this metric.
Taho Pharmaceuticals has a quick ratio of 15.11. It generally indicates good short-term financial strength.
The historical rank and industry rank for Taho Pharmaceuticals's Quick Ratio or its related term are showing as below:
ROCO:6467'
s Quick Ratio Range Over the Past 10 Years
Min: 3.91 Med: 15.09 Max: 19.83
Current: 15.11
During the past 9 years, Taho Pharmaceuticals's highest Quick Ratio was 19.83. The lowest was 3.91. And the median was 15.09.
ROCO:6467's Quick Ratio is ranked better than 96.99% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.455
vs ROCO:6467: 15.11
Taho Pharmaceuticals (ROCO:6467) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Taho Pharmaceuticals Quick Ratio Related Terms
Taho Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for Taho Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taho Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Taho Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Taho Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taho Pharmaceuticals (ROCO:6467) has a Quick Ratio of 15.11 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taho Pharmaceuticals and its competitors. This is near median its historical median of 15.09. Over the past decade, Taho Pharmaceuticals' Quick Ratio has ranged from 3.91 to 19.83. According to the industry distribution chart, Taho Pharmaceuticals ranks #30 out of 998 companies in the Drug Manufacturers industry, placing it in the top 3%.
Is Taho Pharmaceuticals' Quick Ratio too high?
Taho Pharmaceuticals' current Quick Ratio of 15.11 is near median its 10-year median of 15.09. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 19.83. The Drug Manufacturers industry median Quick Ratio is 1.46. Taho Pharmaceuticals' value of 15.11 is 938.5% above this industry median. Based on the distribution chart, Taho Pharmaceuticals ranks #30 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taho Pharmaceuticals ranks #30 out of 998 companies for Quick Ratio. This places Taho Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.46. Taho Pharmaceuticals' value of 15.11 is 938.5% above this benchmark. Historically, Taho Pharmaceuticals' own Quick Ratio has ranged from 3.91 to 19.83 over the past decade. While the company's 10-year median is 15.09 vs. the industry median of 1.46, Taho Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.46, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taho Pharmaceuticals's current Quick Ratio of 15.11 is 938.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taho Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current Quick Ratio is 15.11, which is near median its own 10-year median of 15.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Quick Ratio of 15.11. The current Quick Ratio is 15.11, which is near median its 10-year median of 15.09 and 938.5% above the Drug Manufacturers industry median of 1.46. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Quick Ratio is 15.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score
Get the complete analysis for ROCO:6467
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6467 has been successfully added to your 
